Medicalgorithmics, a GPW-listed developer of globally innovative AI platforms and algorithms for ECG analysis, continues its dynamic growth. The Polish medtech company has entered into a technological partnership with Seers Technology, a South Korean firm specializing in proprietary ECG testing devices. As part of the collaboration, Seers Technology will integrate Medicalgorithmics’ DRP platform and DRAI algorithms with its own hardware solutions to facilitate its entry into the U.S. market. This partnership is the result of meetings held during industry trade fairs in South Korea. This marks the third new contract signed by Medicalgorithmics this year.
Seers Technology is a South Korean technology company providing integrated medical services that combine smart technology with clinical care. The company offers, amongst other things, its own device for performing Holter ECG monitoring. The DRP software and DRAI algorithms developed by Medicalgorithmics will not only enhance the SeersTech device with top-class AI-based software, but will also enable the company to enter the US market with its solutions.
– Our platform for analysing and managing ECG studies, along with our DRAI algorithms, is FDA-certified, which gives us a huge competitive advantage and significantly enhances the appeal of our products. Seers Technology offers excellent hardware, which is also FDA-certified, whereas our partner’s software is not. The partnership with Medicalgorithmics enables them to integrate their tools with our US-certified software and algorithms, thereby significantly accelerating the implementation of their expansion plans in the United States. “We are delighted that Medicalgorithmics’ proprietary solutions will support our new partner in this endeavour – comments Kris Siemionow M.D., CEO of Medicalgorithmics, on the signing of the agreement.
The company has extensive expertise in technological partnerships, built in part through collaboration with firms such as Myant, Fourth Frontier and Wellysis, where Medicalgorithmics software has been integrated with devices from non-US entities seeking to commercialise their products on the US market or globally. This marks Medicalgorithmics’ third commercial success this year. The Polish medtech company had previously signed two new contracts. In early January, the ECG industry innovator entered into a partnership with the US-based IDTF – CardioDiagnostics, which specialises in solutions for cardiological care, with a focus on heart monitoring and remote diagnostics via cloud-based software and devices for clinical electrocardiographic monitoring. Under the terms of the agreement, the Company will supply its partner with innovative AI algorithms for analysing ECG readings – DeepRythm AI (DRAI). Shortly afterwards, a groundbreaking partnership was established with Sharp Tech in Peru, marking the Company’s entry into the Latin American market.